Compare NKSH & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NKSH | SWKH |
|---|---|---|
| Founded | 1891 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.2M | 175.5M |
| IPO Year | N/A | 1999 |
| Metric | NKSH | SWKH |
|---|---|---|
| Price | $32.95 | $17.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 13.0K | 9.9K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | 41.35 | ★ 120.89 |
| EPS | ★ 2.04 | 1.85 |
| Revenue | ★ $51,980,000.00 | $40,149,000.00 |
| Revenue This Year | $2.95 | $52.93 |
| Revenue Next Year | $9.97 | N/A |
| P/E Ratio | $16.43 | ★ $9.43 |
| Revenue Growth | 19.63 | ★ 62.38 |
| 52 Week Low | $23.75 | $13.17 |
| 52 Week High | $33.92 | $20.49 |
| Indicator | NKSH | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 73.37 | 63.72 |
| Support Level | $29.79 | $16.73 |
| Resistance Level | $30.72 | $17.46 |
| Average True Range (ATR) | 0.92 | 0.32 |
| MACD | 0.40 | 0.02 |
| Stochastic Oscillator | 96.46 | 77.60 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.